Living 10 Years in the FutureMike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
PD-L1/PD-1 Pathway: A Security CheckpointDr. Dan Chen explains how immunotherapy may affect the PD-L1/PD-1 pathway, enabling the body to better detect and fight cancer.
Unconventional WisdomHow challenging the status quo led to the discovery of the B cell as a new target in MS.
Understanding ManufacturingWhat does it take to manufacture biologics?
Our PipelineSee the latest progress on differentiated medicines and therapies in development.
Stock InformationCurrent and past market data for Roche, including quotes and dividend history.
The Value of the Right PartnerLearn about the three most important factors a biotech company should consider when looking for a partner.
Latest UpdatesGet the latest on Roche and Genentech initiatives.
Annual ReportsReview and download financial statements and the annual report.
PresentationsView latest presentations from previous events.
Upcoming EventsStay up to date on current IR events.
Frequently Asked QuestionsFind answers to the questions often asked by investors.
Management TeamMeet the leadership team responsible for driving the next evolution of healthcare.
For IR Requests:
Phone: +1 650 225 5566
Fax: +1 650 225 8326
For media inquiries:
Phone: +1 650 467 6800
This website contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for any current or future period will necessarily match or exceed the historical published earnings or earnings per share of Roche. Information accessed herein may not under any circumstances be used for the purpose of, or in connection with, the quotation of any securities on an automated inter-dealer quotation system within the meaning of Rule 12g3-2(b) under the Securities Exchange Act of 1934.